USCOM LIMITED — Capital/Financing Update 2009

Jul 5, 2009

==> picture [71 x 87] intentionally omitted <==

MARKET ANNOUNCEMENT

• FY 2009 Update

o Partnership with Spacelabs Healthcare

o Revenue increased by 70%

o Q4 Cash flow positive

• Approaching Profitability

o Inclusion in Pediatric Sepsis Guidelines

Monday, 6 July 2009: Uscom (ASX Code: UCM) today informed shareholders of progress and achievements during the 2009 Financial Year.

Uscom CEO, Mr. Paul Butler said “We started this year focused on achieving key milestones. I am pleased to report that we have closed off the financial year having achieved these milestones and are well positioned for the coming year.”

Uscom entered a distribution partnership with Spacelabs Healthcare in December 2008 expanding Uscom distribution in the USA, Latin America and Europe. At the same time, OSI Systems (NASDAQ: OSIS) Spacelabs parent company, acquired a 5% interest in Uscom along with options for a further 5%.

Product revenues have increased by approximately 70% over the prior financial year to in excess of $1.6 million (subject to audit). In the fourth quarter of the financial year Uscom achieved a cash flow neutral position from normal operations, with an expected net inflow of approximately $500k due to tax returns and grants.

The company also approached profitability for the last half of the financial year. Whilst this outcome is subject to confirmation in the final audit, we believe that this is a significant achievement for the company. Going forward, financial performance will be very much dependent upon ongoing Spacelab marketing efforts and the level of resulting end user sales.

Another major achievement for the 09 year was the inclusion of the Uscom technology in the Global Pediatric Sepsis Guidelines. Becoming the standard of clinical care in pediatrics is a major scientific milestone for USCOM.

Mr Rob Phillips, Executive Chairman and Director of Clinical Science said “This has been an excellent year for Uscom reflecting our focus on clearly identified objectives. Our results for FY 2009 support the strategic plan that we have developed and pursued.”

Uscom Limited Level 7, 8-10 Loftus Street Sydney NSW 2000 Australia Phone: 61-2-9247 4144 Fax: 61-2-9247 8157 ABN: 35 091 028 090

www.uscom.com.au

==> picture [71 x 87] intentionally omitted <==

About Uscom

Uscom Limited is an Australian medical device company, listed on the Australian Stock Exchange since December 2003. Uscom has developed a device for the safe and accurate measurement of cardiac output, a non-invasive alternative to the current invasive methods. Uscom offers a completely safe, painless and quick method of accurately measuring how well the heart is pumping. With its real-time beat-to-beat information across multiple parameters of cardiac function and advanced serial measurement capabilities, clinicians can accurately quantify the impact of therapy. The device is ideally suited to the Emergency Care setting where it is critical to monitor changes in cardiac output as fluids are applied.

The Company has secured regulatory approval for sale of the Uscom Monitor in Australia, Europe and a number of Asian markets, including Japan, China and Taiwan. Uscom also has a CE Mark certification for Europe and a license from the State Food & Drug Administration for China. The Company received the necessary regulatory clearance for the United States market in February 2005 with the receipt of a 510K Pre Market Notification from the US Food & Drug Administration (FDA).

Uscom Contacts Paul Butler Chief Executive Officer Office: +1 646 379 3278 paul.butler@uscom.com.au

Rob Phillips Executive Chairman Office: 02 9247 4144 rob@uscom.com.au

Uscom Limited Level 7, 8-10 Loftus Street Sydney NSW 2000 Australia www.uscom.com.au Phone: 61-2-9247 4144 Fax: 61-2-9247 8157 ABN: 35 091 028 090